Key result
Tailored DOAC therapy may optimize the balance between bleeding and thrombosis risks compared to fixed-dose regimens, particularly in patients with extremes of body weight or impaired kidney function.
Why the study?
Does tailored DOAC therapy based on drug levels improve the balance between bleeding and thrombosis compared to fixed-dose regimens in patients with thromboembolic diseases?
Does tailored DOAC therapy based on drug levels improve the balance between bleeding and thrombosis compared to fixed-dose regimens in patients with thromboembolic diseases?
Answers are grounded in this paper and cite their sources.
This opinion article suggests that tailoring DOAC therapy based on drug levels, rather than using standard fixed doses, could potentially optimize the balance between bleeding and thrombosis risks, particularly in special populations.
Direct oral anticoagulants (DOACs) are increasingly used for treatment and prevention of thromboembolic diseases, used in fixed dose regimens. Although their safety and efficacy profiles are considered optimal, clinical events still occur. Given that anticoagulation treatment is a delicate balance between clotting and bleeding, it is possible that an optimal target spot exists where the effect of anticoagulation achieves both the lowest possible risk of bleeding and thrombosis. Other currently available anticoagulants (ie, vitamin K antagonists and heparins) provide important clues for this. If such a target spot exists, tailored DOAC therapy may further benefit patients. This opinion article summarizes the current available evidence that suggests that such a tailored strategy could work. It also describes research suggestions for conducting studies in patient populations such as patients with extremes of body weight or impaired kidney function to evaluate whether tailored treatment with DOACs could lead to better patient outcomes.
No takes yet. Share an insight, caveat, or question.
Toorop et al. (2020) conducted a review in Thromboembolic diseases. Tailored DOAC therapy vs. Fixed dose regimens was evaluated. Tailored DOAC therapy may optimize the balance between bleeding and thrombosis risks compared to fixed-dose regimens, particularly in patients with extremes of body weight or impaired kidney function.
Synapse has enriched 10 related papers. Consider them for comparative context: